Insider Selling: Zevra Therapeutics (NASDAQ:ZVRA) Insider Sells $40,026.39 in Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) insider Adrian Quartel sold 4,533 shares of the company’s stock in a transaction dated Friday, January 30th. The shares were sold at an average price of $8.83, for a total transaction of $40,026.39. Following the completion of the sale, the insider directly owned 9,723 shares in the company, valued at approximately $85,854.09. The trade was a 31.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Zevra Therapeutics Price Performance

Shares of NASDAQ ZVRA opened at $8.94 on Thursday. The company has a quick ratio of 8.57, a current ratio of 8.62 and a debt-to-equity ratio of 0.46. The business’s 50 day moving average price is $8.68 and its two-hundred day moving average price is $9.40. The company has a market cap of $503.32 million, a PE ratio of 19.02 and a beta of 0.99. Zevra Therapeutics, Inc. has a twelve month low of $6.19 and a twelve month high of $13.16.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.03. The company had revenue of $26.06 million during the quarter, compared to analysts’ expectations of $26.64 million. Zevra Therapeutics had a negative return on equity of 51.40% and a net margin of 41.93%. On average, analysts predict that Zevra Therapeutics, Inc. will post -1.95 EPS for the current year.

Analysts Set New Price Targets

ZVRA has been the topic of several research analyst reports. Weiss Ratings reissued a “sell (d+)” rating on shares of Zevra Therapeutics in a research report on Friday, January 9th. HC Wainwright set a $26.00 price objective on Zevra Therapeutics in a report on Tuesday, December 30th. Cantor Fitzgerald decreased their target price on Zevra Therapeutics from $29.00 to $24.00 and set an “overweight” rating on the stock in a research report on Thursday, November 6th. Wall Street Zen raised Zevra Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Finally, Canaccord Genuity Group reduced their price target on Zevra Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a research note on Thursday, November 6th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $22.80.

Institutional Investors Weigh In On Zevra Therapeutics

Several institutional investors have recently made changes to their positions in ZVRA. Marshall Wace LLP bought a new position in shares of Zevra Therapeutics in the third quarter worth $8,676,000. Rubric Capital Management LP grew its stake in Zevra Therapeutics by 60.8% during the second quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company’s stock worth $17,253,000 after buying an additional 740,584 shares in the last quarter. Royce & Associates LP bought a new position in Zevra Therapeutics in the 3rd quarter valued at about $6,574,000. Adage Capital Partners GP L.L.C. raised its position in shares of Zevra Therapeutics by 15.2% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company’s stock valued at $36,720,000 after buying an additional 550,000 shares in the last quarter. Finally, Nantahala Capital Management LLC raised its position in shares of Zevra Therapeutics by 34.0% in the 3rd quarter. Nantahala Capital Management LLC now owns 1,971,936 shares of the company’s stock valued at $18,753,000 after buying an additional 500,000 shares in the last quarter. 35.03% of the stock is currently owned by institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.